Becton, Dickinson and Company $BDX Stock: Pinnacle Associates Ltd. Raises Holdings

Pinnacle Associates Ltd. grew its position in Becton, Dickinson and Company (NYSE:BDX) by 12.2% during the third quarter, HoldingsChannel reports. The firm owned 25,922 shares of the medical instruments supplier’s stock after buying an additional 2,811 shares during the period. Pinnacle Associates Ltd.’s holdings in Becton, Dickinson and Company were worth $4,640,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of BDX. Brown Lisle Cummings Inc. boosted its position in Becton, Dickinson and Company by 9.2% during the second quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock valued at $97,000 after acquiring an additional 54 shares during the last quarter. Pension & Wealth Management Advisors Inc. grew its holdings in Becton, Dickinson and Company by 12.3% during the 3rd quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock worth $94,000 after acquiring an additional 56 shares during the period. Elevation Point Wealth Partners LLC grew its holdings in Becton, Dickinson and Company by 3.7% during the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock worth $256,000 after acquiring an additional 60 shares during the period. Private Harbour Investment Management & Counsel LLC raised its position in shares of Becton, Dickinson and Company by 1.1% in the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock worth $834,000 after acquiring an additional 62 shares in the last quarter. Finally, NorthRock Partners LLC raised its position in shares of Becton, Dickinson and Company by 2.0% in the 2nd quarter. NorthRock Partners LLC now owns 3,295 shares of the medical instruments supplier’s stock worth $499,000 after acquiring an additional 65 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares of the company’s stock, valued at $3,717,022.80. The trade was a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 6,906 shares of company stock valued at $1,265,855. 0.40% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a research note on Friday, August 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Weiss Ratings raised Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. Piper Sandler lifted their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Finally, Wolfe Research began coverage on Becton, Dickinson and Company in a research note on Tuesday. They issued an “outperform” rating on the stock. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average price target of $185.07.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $200.21 on Friday. The stock has a market cap of $55.16 billion, a P/E ratio of 60.30, a P/E/G ratio of 13.10 and a beta of 0.21. The business’s fifty day moving average is $185.10 and its 200 day moving average is $164.86. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $200.47. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.